ALGN trades 14.5% below Wall Street's consensus target of $190.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ALGN achieves its forward estimates and maintains a stable P/E multiple of 14.9x. This scenario reflects the blended consensus of 33 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Align Technology, Inc. (ALGN) has a Wall Street consensus price target of $190.00, based on estimates from 33 covering analysts. With the stock currently trading at $166.00, this represents a potential upside of +14.5%. The company has a market capitalization of $11.89B.
Analyst price targets range from a low of $162.00 to a high of $215.00, representing a 28% spread in expectations. The median target of $189.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ALGN trades at a trailing P/E of 29.4x and forward P/E of 14.9x. Analysts expect EPS to grow +60.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $261.69, with bear and bull scenarios of $164.86 and $344.80 respectively. Model confidence stands at 47/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 XRAYDENTSPLY SIRONA Inc. | $1.9B | $9.46 | $12.14 | +28.3% | Hold | 6.2x | 32 |
 HSICHenry Schein, Inc. | $9.8B | $86.05 | $97.14 | +12.9% | Buy | 15.7x | 34 |
 NVSTEnvista Holdings Corp | $4.1B | $25.17 | $28.60 | +13.6% | Hold | 16.3x | 20 |
 IDXXIDEXX Laboratories, Inc. | $53.3B | $676.04 | $716.67 | +6.0% | Buy | 45.5x | 23 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 ISRGIntuitive Surgical, Inc. | $160.0B | $452.80 | $485.44 | +7.2% | Buy | 40.3x | 57 |
 GKOSGlaukos Corporation | $13.2B | $224.41 | $218.70 | -2.5% | Buy | 332.7x | 25 |
 TMDXTransMedics Group, Inc. | $3.0B | $88.24 | $100.43 | +13.8% | Buy | 60.2x | 13 |
 MMM3M Company | $95.5B | $185.15 | $188.13 | +1.6% | Buy | 20.3x | 33 |
 IPGPIPG Photonics Corporation | $2.8B | $65.31 | $121.00 | +85.3% | Buy | 59.2x | 27 |
Quick answers to the most common questions about buying ALGN stock.
Align Technology, Inc. (ALGN) has a consensus 12-month price target of $190, implying 14.5% upside from $166. The 33 analysts covering ALGN see moderate appreciation potential.
ALGN has a consensus rating of "Buy" based on 33 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $190 implies 14.5% upside from current levels.
With a forward P/E of 14.8984x, ALGN trades at a relatively low valuation. The consensus target of $190 implies 14.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $215 for ALGN, while the most conservative target is $162. The consensus of $190 represents the median expectation. Our quantitative valuation model projects a bull case target of $345 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ALGN is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 9 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ALGN stock forecast based on 33 Wall Street analysts shows a consensus price target of $190, with estimates ranging from $162 (bear case) to $215 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $262, with bear/bull scenarios of $165/$345.
Our quantitative valuation model calculates ALGN's fair value at $262 (base case), with a bear case of $165 and bull case of $345. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 47/100.
ALGN trades at a forward P/E ratio of 14.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 29.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on ALGN, with a "Buy" consensus rating and $190 price target (14.5% upside). 22 of 33 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ALGN analyst price targets range from $162 to $215, a 28% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $190 consensus represents the middle ground. Our model's $165-$345 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.